ArticleIndian pediatrics2026
Cyclophosphamide and Topotecan in Relapsed and Refractory Pediatric Extracranial Solid Tumors: A Retrospective Analysis.
Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effectiveness and safety of cyclophosphamide and topotecan in children with relapsed or refractory extracranial solid tumors.
methodsThis study included children with relapsed or refractory extracranial solid tumors treated with cyclophosphamide (250 mg/m
resultsEighteen patients with median (range) age 6 (2-13) years (72% boys) with diagnoses of neuroblastoma (61%), Ewing sarcoma (22%), and rhabdomyosarcoma (17%), were analysed. Median of 4-cycles of chemotherapy was given, mostly as second-line (78%). Among 15 evaluable patients, responses were complete-response (CR, n = 1), partial response (PR, n = 3), stable disease (SD, n = 2), and progressive disease (n = 9); disease control rate (CR + PR + SD) 40%. The median EFS and OS were 3.65 months and 9.72 months, respectively, with 1-year EFS and OS rates of 33% and 45%. There was no treatment-related mortality.
conclusionCyclophosphamide-topotecan shows efficacy and acceptable safety in pediatric relapsed/refractory solid cancers, highlighting the need for better strategies to improve outcomes.
Indexed as
Identifiers
41499028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.